PLIANT THERAPEUTICS INC (PLRX)
US7291391057 - Common Stock
Overall PLRX gets a fundamental rating of 2 out of 10. We evaluated PLRX against 195 industry peers in the Pharmaceuticals industry. While PLRX seems to be doing ok healthwise, there are quite some concerns on its profitability. PLRX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PLRX had negative earnings in the past year.
PLRX had a negative operating cash flow in the past year.
PLRX had negative earnings in each of the past 5 years.
PLRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PLRX has a Return On Assets of -45.25%. This is in the lower half of the industry: PLRX underperforms 60.22% of its industry peers.
Looking at the Return On Equity, with a value of -58.32%, PLRX is in line with its industry, outperforming 53.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.25% | ||
| ROE | -58.32% | ||
| ROIC | N/A |
ROA(3y)-36.88%
ROA(5y)-26.09%
ROE(3y)-40.76%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PLRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLRX has more shares outstanding
Compared to 5 years ago, PLRX has more shares outstanding
The debt/assets ratio for PLRX has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.58, we must say that PLRX is in the distress zone and has some risk of bankruptcy.
PLRX has a better Altman-Z score (1.58) than 62.90% of its industry peers.
PLRX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PLRX (0.09) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.58 |
ROIC/WACCN/A
WACC10.78%
2.3 Liquidity
A Current Ratio of 10.26 indicates that PLRX has no problem at all paying its short term obligations.
PLRX's Current ratio of 10.26 is amongst the best of the industry. PLRX outperforms 83.33% of its industry peers.
PLRX has a Quick Ratio of 10.26. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PLRX (10.26) is better than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.26 | ||
| Quick Ratio | 10.26 |
3. Growth
3.1 Past
PLRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.71%.
PLRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
PLRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -66.44% yearly.
EPS 1Y (TTM)-19.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.71%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.44%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, PLRX will show a small growth in Earnings Per Share. The EPS will grow by 4.68% on average per year.
The Revenue is expected to grow by 139.09% on average over the next years. This is a very strong growth
EPS Next Y-34.47%
EPS Next 2Y-21.88%
EPS Next 3Y-16.07%
EPS Next 5Y4.68%
Revenue Next Year-100%
Revenue Next 2Y6.06%
Revenue Next 3Y43.58%
Revenue Next 5Y139.1%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PLRX. In the last year negative earnings were reported.
Also next year PLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PLRX's earnings are expected to decrease with -16.07% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.88%
EPS Next 3Y-16.07%
5. Dividend
5.1 Amount
PLRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PLIANT THERAPEUTICS INC
NASDAQ:PLRX (1/14/2025, 11:17:39 AM)
11.48
-0.29 (-2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners118.07%
Inst Owner Change0.01%
Ins Owners2.34%
Ins Owner Change0%
Market Cap698.56M
Analysts85.26
Price Target40.12 (249.48%)
Short Float %12.14%
Short Ratio13.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.21%
Min EPS beat(2)-6.32%
Max EPS beat(2)3.9%
EPS beat(4)3
Avg EPS beat(4)3.84%
Min EPS beat(4)-6.32%
Max EPS beat(4)16.88%
EPS beat(8)6
Avg EPS beat(8)3.93%
EPS beat(12)9
Avg EPS beat(12)4.73%
EPS beat(16)11
Avg EPS beat(16)4.89%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-66.24%
Revenue beat(12)4
Avg Revenue beat(12)-19.67%
Revenue beat(16)5
Avg Revenue beat(16)-19.76%
PT rev (1m)-0.42%
PT rev (3m)-2.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.88%
EPS NY rev (1m)0%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-91.54%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.02 | ||
| P/tB | 2.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.34
EYN/A
EPS(NY)-4.1
Fwd EYN/A
FCF(TTM)-2.25
FCFYN/A
OCF(TTM)-2.18
OCFYN/A
SpS0
BVpS5.68
TBVpS5.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.25% | ||
| ROE | -58.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.88%
ROA(5y)-26.09%
ROE(3y)-40.76%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 173.87% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.26 | ||
| Quick Ratio | 10.26 | ||
| Altman-Z | 1.58 |
F-Score1
WACC10.78%
ROIC/WACCN/A
Cap/Depr(3y)91.12%
Cap/Depr(5y)95.33%
Cap/Sales(3y)34.07%
Cap/Sales(5y)21.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.71%
EPS Next Y-34.47%
EPS Next 2Y-21.88%
EPS Next 3Y-16.07%
EPS Next 5Y4.68%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.44%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y6.06%
Revenue Next 3Y43.58%
Revenue Next 5Y139.1%
EBIT growth 1Y-27.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.39%
EBIT Next 3Y-19.4%
EBIT Next 5YN/A
FCF growth 1Y-59.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.69%
OCF growth 3YN/A
OCF growth 5YN/A